Karan Mediratta, Sara El-Sahli, Marie Marotel, Muhammad Z Awan, Melanie Kirkby, Ammar Salkini, Reem Kurdieh, Salman Abdisalam, Amit Shrestha, Chiara Di Censo, Andrew Sulaiman, Sarah McGarry, Jessie R Lavoie, Zhen Liu, Seung-Hwan Lee, Xuguang Li, Giuseppe Sciumè, Vanessa M D'Costa, Michele Ardolino, Lisheng Wang
INTRODUCTION: Chemotherapy remains the mainstay treatment for triple-negative breast cancer (TNBC) due to the lack of specific targets. Given a modest response of immune checkpoint inhibitors in TNBC patients, improving immunotherapy is an urgent and crucial task in this field. CD73 has emerged as a novel immunotherapeutic target, given its elevated expression on tumor, stromal, and specific immune cells, and its established role in inhibiting anti-cancer immunity. CD73-generated adenosine suppresses immunity by attenuating tumor-infiltrating T- and NK-cell activation, while amplifying regulatory T cell activation...
2024: Frontiers in Immunology